Introduction
Systolic blood pressure (SBP) is becoming increasingly recognized as a powerful risk factor for allcause mortality, coronary heart disease (CHD), stroke, and end-stage renal disease as well as a more important factor than diastolic blood pressure (DBP) for the diagnosis, classification, staging, and management of hypertension. [1] [2] [3] [4] [5] [6] The presence of systolic hypertension amplifies the impact of other risk factors such as diabetes and hypercholesterolemia on occurrence of cardiovascular (CV) events. 2, 7, 8 Prevention, detection, and control of SBP is therefore a major goal in hypertension management, as reflected by the prominence of SBP in the most recent hypertension management guidelines. [9] [10] [11] Elevated SBP is particularly prevalent in persons over the age of 50 years, and occurs as a consequence of the aging process. With increasing age, a gradual stiffening of the large arteries occurs, with an attendant loss of elasticity and compliance, and this, in turn, results in a continuous elevation in SBP. 2, 12, 13 Indeed, in persons over 60 years of age, isolated systolic hypertension (ISH, defined as SBP 4140 mmHg with DBP o90 mmHg) represents the most common form of hypertension, accounting for 65% of all cases.
14 . While the mortality and morbidity benefits of reducing systolic hypertension are clear, as shown by several interventional trials including Systolic Hypertension in the Elderly Program (SHEP), Systolic Hypertension in Europe (Syst-Eur), and Systolic Hypertension in China (Syst-China), [15] [16] [17] SBP and its clinical consequences remain suboptimally controlled in many hypertensive patients. 18 Thus, there is a need for well-tolerated therapies which impact the underlying causes as well as CV complications of systolic hypertension. Angiotensin II (AII) is believed to play a central role in the development of endothelial dysfunction and vascular remodelling associated with hypertension. 19 Thus, angiotensin II antagonists (AIIAs) may be especially useful in attenuating systolic hypertension. 2, 12 The purpose of this article is to review the prevalence and pathophysiology of systolic hypertension, to summarize evidence associating systolic hypertension with an increased risk of CV disease, and, finally, to review recent therapeutic advances in pharmacotherapy of systolic hypertension, with an emphasis on AIIAs. Relevant studies were identified through a MEDLINE search of Englishlanguage articles published between 1990 and 2004. The search terms included AIIAs, angiotensin receptor blockers, systolic hypertension, ISH, clinical trial, CV, and stroke. Articles describing major clinical studies, new data, or new mechanisms pertinent to the treatment of systolic hypertension were selected for this review.
High prevalence of SBP SBP increases with age up to the 8th or 9th decades of life, whereas DBP rises until middle age, then peaks or declines slightly thereafter. 20 As a consequence, systolic hypertension, especially ISH, is especially common in elderly individuals. According to National Health and Nutrition Examination Survey (NHANES) III, ISH is the primary type of hypertension in untreated and inadequately treated hypertensive patients over the age of 50 years and comprises 87% of hypertensive patients in the sixth decade of life. 21 Systolic hypertension therefore represents a substantial health care problem, which is exacerbated by the fact that normalization of SBP is more difficult to attain by drug therapy. 22 
Pathophysiology of systolic hypertension
Elevated SBP is believed to largely reflect progressive structural and functional deterioration of the arterial wall, involving endothelial dysfunction, atherosclerosis, aortic stiffness, and increased wall stress and pulse pressure ( Figure 1) . 2 According to this hypothesis, atherosclerosis, triggered by vascular endothelial damage and mechanical strain from each stroke volume, plays a central pathophysiological role. 2 Atherosclerosis progressively leads to the replacement of elastin by collagen and other structural proteins and the build up of calcium in the arterial wall, 23, 24 and this, in turn, leads to hypertrophy and fibrosis of arterial smooth muscle and a diminished capacity of arteries to dampen the pressure wave produced by ventricular contraction. 2 Several factors lead to an increased risk of developing arterial stiffness, including obesity, diabetes, familial hypercholesterolemia, and homocysteine levels. 25 The widening of pulse pressure, increased wave reflection, and systolic hypertension that these processes produce eventually contribute to the development of a spectrum of CV diseases such as cardiac and vascular hypertrophy and target organ damage. 24 The renin-angiotensin system plays an important role in the pathogenesis of vascular hypertrophy and arterial stiffness. 19 AII, the principal biological effector of this system, may be intimately involved in the pathogenesis of systolic hypertension through several mechanisms, including decreasing the elastin content and increasing the collagen content of the arterial wall, thickening and fibrotic remodelling of the vascular intima, and proliferating small muscle cells in the arterial wall, resulting in increased thickness, stiffening, and partial loss of contractility. 19, 24 Thus, pharmacologic blockade of AII's effect may, therefore, offer hitherto unrecognized benefits on age-related vascular damage and provide particular benefits in patients with systolic hypertension.
Link between ISH and CV risk
For a large part of the previous century, physicians have diagnosed and treated hypertension based on the belief that DBP better predicts CV risk than SBP. 26 This view began to change, however, as a result of early observations by the insurance companies, which found that cardiovascular mortality rose more steeply in relation to SBP than DBP. 27, 28 These findings were later corroborated by the Framingham study, which provided the first definitive evidence that elevated SBP better predicts CV disease and stroke than elevated DBP, 29, 30 and numerous epidemiological studies. 1, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Analysis of data accrued over 20 years from US prospective population studies clearly showed that SBP has a continuous, graded, strong, independent, and aetiologically significant relationship to mortality from CHD, stroke, and all CV disease as well as all-cause mortality and life expectancy. 42 In the case of middle-aged and older persons, SBP related more strongly to risk than DBP, such that, at every DBP level, a higher SBP resulted in greater CV disease risk and curtailment of life expectancy. 42 The Prospective Studies Collaboration, which encompassed one million adults and 12.7 million personyears at risk, similarly showed that SBP was related to mortality to a value of 115 mmHg, and that, for ages 40-69 years, a 20 mmHg difference in usual SBP (equivalent to a 10 mmHg usual DBP) produced a two-fold difference in the stroke death rate, and a two-fold difference in the death rates from ischaemic heart disease (IHD) and from other vascular causes. 43 From a clinical trial perspective, one of the most noteworthy and largest studies (316 099 men) with respect to systolic hypertension and CV disease risk was the Multiple Risk Factor Intervention Trial (MRFIT). 1 This study provided solid evidence of a continuous and graded influence of SBP and CHD mortality rate down to 140 mmHg, and also showed that the greatest CHD mortality rate occurred in patients with the highest SBP and the lowest DBP ( Figure 2 ). 1 
Overview of managing systolic hypertension
Several treatment guidelines, issued by the Joint National Committee on the Prevention, Detection, and Treatment of High Blood Pressure (JNC VII), European Society of Hypertension/European Society of Cardiology, World Health Organization/ International Society of Hypertension, and British Hypertension Society, all recognize the importance to controlling SBP. 9, 11, 44, 45 The overall recommendation is that drug treatment should be considered in high-risk patients whose SBP exceeds 140 mmHg and that all hypertensive patients should aim for SBP below 140 mmHg.
Although it is now generally recognized that SBP is a more valuable measure not only in evaluating but also in controlling hypertension, an urgent need exists to educate practitioners on the importance of reducing SBP as well as DBP in hypertensive patients. However, SBP is notoriously difficult to normalize in hypertensive patients even in controlled clinical trials, and, thus, most hypertensive patients do not attain the minimum SBP goal of o140 mmHg.
Lack of control of SBP is often observed even when multiple pharmacologic agents are used in combination. In a multicountry survey of blood pressure control, approximately 50% of hypertensive patients were found to attain DBP control (o90 mmHg), whereas only 5% attained SBP control (o140 mgHg). 46 Similarly, PAMELA, a study conducted in Northern Italy, reported a similar poor SBP response rate, with SBP control occurring in 8.9% of treated hypertensives, compared with 15.4% for DBP. 47 Indeed, even in the recently completed ALLHAT study, SBP control occurred in 60% of hypertensive patients vs 90% for DBP control. According to a recent review of 10 antihypertensive drug trials, DBP was invariably below 90 mmHg in most trials, whereas SBP remained above or slightly below 140 mgHg-approximately 90% of patients attained goal DBP values but only 50% attained SBP goal. 48 The key question in hypertension management is, therefore, 'How do we achieve SBP goals in actual clinical practice?'. Treatment of systolic hypertension, including ISH in the elderly, may involve both pharmacologic agents (either alone or in combination) and nonpharmacologic interventions. In patients with mild hypertension, lifestyle modifications alone to reduce weight, dietary sodium intake, and alcohol intake, and increased physical activity have been shown to produce beneficial effects on blood pressure. 49 However, lifestyle changes alone rarely achieve the desired SBP goals and most patients will require administration of one or more antihypertensive agents.
A number of studies collectively show that pharmacological lowering of SBP decreases CV events. Based on the findings of several placebocontrolled studies in elderly patients with ISH, pharmacologic management of SBP typically involves a diuretic-based or a CCB-based regimen. SHEP and Syst-Eur showed significant reductions in stroke, coronary vascular disease, heart failure, and mortality when ISH patients received either a chlorthalidone-atenolol regimen or a nitrendipinehydrochlorothiazide-enalapril regimen. 15, 16 Similar findings were reported in the Syst-China study. 17 While these placebo-controlled trials show CV benefits in patients with ISH, many patients with ISH continue to have elevated SBP. Thus, even in the clinical trial setting, effective control of SBP is challenging. 18 Failure to attain control of SBP may involve several issues such as occurrence of side effects, which can limit optimal dosing and patient compliance with therapy. Other possible factors contributing to a lack of control of SBP in hypertensive patients include the failure of physicians to place appropriate emphasis on SBP control and the difficulties in reversing arterial wall thickening that plays a key pathophysiological role in abnormally elevated SBP. Difficulties in the management of multiple drug regimens that may be required to normalize SBP also play a potentially important role. In this regard, lack of tolerability of a regimen based on combination therapy is an important factor.
Thus, there is a need for newer therapeutic strategies that are better tolerated and more that at the same time effectively reduce SBP, for example, by reversing the arterial wall thickening. In addition, physicians should be urged to place greater emphasis on controlling SBP in hypertensive patients.
AIIAs and systolic hypertension
Since AII is believed to participate in the process of vascular remodelling and development of endothelial dysfunction frequently observed in hypertension patients, AIIAs may be especially useful in treating systolic hypertension. Activation of the renin-angiotensin system and sympathetic nervous system play a key role in mediating the haemodynamic changes that bring about systolic hypertension (ie, increased peripheral resistance, reduced arterial compliance, increased reflected waves and sodium retention). 19 AIIAs may thus interfere with key mechanisms involved in the pathogenesis of ISH. They are also well tolerated, thereby potentially impacting the ability of hypertensive patients to stay on therapy and achieve goal SBP.
Overview of AII antagonist treatment trials in systolic hypertension

Losartan
The effects of losartan on SBP in patients with ISH have been reported in several placebo and active comparator trials. [50] [51] [52] In a first prospective, placebocontrolled trial of an AIIA in ISH, Cushman et al 50 compared the antihypertensive efficacy and tolerability of a losartan-based regimen and placebo in 308 patients with ISH. At 12 weeks, the placeboadjusted mean change from baseline in trough sitting SBP was À11.6 mmHg, a value comparable to placebo-adjusted reductions seen in SHEP and Syst-Eur trials. 15, 16 A double-blind, randomized, multi-country study by Farsang et al 51 compared the efficacy and tolerability of losartan and atenolol after 16 weeks of treatment in 273 patients with a sitting SBP of 160-205 mmHg, and a sitting DBP o 90 mmHg. Patients whose SBP was not controlled were given additional treatment of HCTZ. While similar significant reductions in sitting SBP occurred in the losartan and atenolol groups, patients receiving losartan had a lower withdrawal rate due to clinical adverse events (1.5 vs 7.2%, P ¼ 0.035) and significantly fewer drug-related clinical adverse events (10.4 vs 20.3, P ¼ 0.029).
Similar findings were also reported in a study by Volpe et al, 52 who compared a losartan-based and an amlodipine-based regimen on trough sitting SBP in a multicenter, prospective, randomized, doubleblind, parallel-group study. Losartan and amlodipine produced comparable clinically relevant reductions in SiSBP; although losartan produced fewer clinical adverse events (67.8 vs 79.8%, Pp0.001) and discontinuations (6.0 vs 14.6%, Pp0.001) compared with amlodipine.
Eprosartan
This AIIA has been shown to lower blood pressure effectively in hypertensive patients over the recommended dose range of 600-800 mg once daily. 53 In patients with severe hypertension, eprosartan may be more effective than enalapril in reducing SBP. 54 The blood pressure lowering effect of eprosartan appeared to be similar to that of enalapril with respect to DBP (mean change from baseline À20.1 vs À16.2 mmHg, respectively), but superior to enalapril with respect to SBP (mean change from baseline À29.1 vs À21.2 mmHg, respectively, P ¼ 0.025). However, in elderly patients with predominantly systolic hypertension, eprosartan and enalapril were equally effective in reducing sitting SBP and DBP. 55 
Valsartan
The effects of valsartan on SBP have also been evaluated in several placebo-controlled and activecontrol trials. In a study by Neutel et al, 56 146 elderly patients with systolic hypertension, with or without diastolic hypertension, received valsartan 80 mg or placebo once daily for 4 weeks and were then force-titrated to valsartan 160 mg or matching placebo once daily for an additional 4 weeks. The reduction in trough sitting SBP with valsartan was superior to placebo (19.2 vs 8.8 mmHg, respectively, Po0.001). Valsartan also produced superior reductions in trough mean sitting DBP compared with placebo (5.2 vs 1.2 mmHg, respectively, Po0.001). Tolerability was comparable to that seen with placebo.
Malacco et al 57 reported the blood pressure lowering effects of valsartan and amlodipine in elderly patients with ISH in Italy. In this 24-week, randomized, double-blind, active-controlled study, valsartan given alone or in combination with HCTZ showed similar efficacy but better tolerability than amlodipine-based treatment. Adverse events occurred in 31.9% of those receiving amlodipine vs 20.2% of the patients receiving valsartan (Po 0.003).
Candesartan
A number of studies have investigated the effects of candesartan on SBP. The efficacy and safety of candesartan and HCTZ (alone and in combination) was studied in a double-blind, randomized, placebo-controlled study in older patients with systolic hypertension. 58 Candesartan and low-dose HCTZ hydrochlorothiazide were effective and well-tolerated antihypertensive agents in ISH and produced additive effects when administered together. Both drugs were well tolerated either as monotherapy or in combination.
A study by Neutel et al 59 in patients with ISH found that candesartan produced a dose-related decrease in SBP, with a smaller decrease in DBP, resulting in a substantial reduction in pulse pressure. The candesartan dose-blood pressure response was consistent across age, sex, and race. Adverse events were infrequent and led to withdrawal in only 8% of patients.
According to a large-scale study, candesartan either alone or as add-on therapy was effective for the control of systolic or diastolic hypertension across a wide range of demographic groups. 60 This study involved a total of 6465 hypertensive patients, of which 1014 patients were diagnosed with ISH. Patients had either untreated or uncontrolled hypertension despite treatment with a variety of antihypertensive agents. In the cohort of patients with ISH, candesartan monotherapy reduced SBP/ DBP by 17.0/4.4 mmHg. As add-on therapy, candesartan reduced SBP/DBP further by 17.4/5.1 mmHg in patients receiving diuretics, 15.6/3.6 mmHg in those receiving calcium antagonists, by 14.0/ 4.8 mmHg in those receiving beta blockers, and by 13.4/4.3 mmHg in those receiving ACE inhibitors. Candesartan was well tolerated with only 6.8% of the total cohort of 6465 patients withdrawing due to adverse events.
Telmisartan
In patients with mild to moderate hypertension, telmisartan at dosages of 40-160 mg daily significantly reduced SBP and DBP compared with placebo and was at least as effective as atenolol, amlodipine, or lisinopril. 61, 62 In the AII receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study, telmisartan (20-80 mg daily) produced significant reductions in SBP (16.9 mmHg at 80 mg dose) compared with placebo (11.4 mmHg) and produced reductions comparable to HCTZ 12.5 mg (15.7 mmHg). 63 As with other AIIAs, the tolerability of telmisartan was similar to that of placebo.
Irbesartan Irbesartan produces 24-h blood pressure control in patients with mild-to-moderate hypertension and appears to be as effective as enalapril, atenolol, and amlodipine, and more effective than valsartan in terms of absolute reduction in BP and response rates. 64 In a study of elderly patients aged 65 years or older with mild to moderate hypertension, irbesartan decreased mean sitting SBP by 10.1 mmHg, a value that was similar to that seen with enalapril (11.6 mmHg). 65 As yet, no study has addressed the effects of irbesartan in patients with ISH. Irbesartan is well tolerated with an overall incidence of adverse events similar to that with placebo. 64 Olmesartan Olmesartan medoxomil (20-40 mg once daily), the latest addition to the ARB class, significantly reduces systolic and diastolic blood pressure in hypertensive patients of a magnitude comparable to that seen with amlodipine or other angiotensin receptor blockers, including losartan, valsartan, irbesartan. [66] [67] [68] [69] As yet, however, no studies have been reported in patients with ISH. Olmesartan appears to be well tolerated; only dizziness occurred with greater frequency with olmesartan medoxomil (3% of patients) than with placebo. 67 
Combination therapy
In a large proportion of patients with hypertension, combination therapy is essential to achieve BP control, especially with respect to SBP. This point is illustrated by the results of the HOT trial, 70 which showed that normalization of SBP is usually only attained through administration of two or more agents. Indeed, several current hypertension guidelines (eg, Hypertension in African Americans Working Group (HAAWG) JNC7) and the latest European guidelines acknowledge that many patients with hypertension should receive a combination of two agents as initial therapy. 9, 11, 71 Combination therapy using AIIAs and a low-dose thiazide diuretic such as HCTZ offers a number of potential benefits in antihypertensive therapy, including more effective blood pressure control and the likelihood of a better tolerability profile that can help patients stay on therapy. 72 The efficacy of losartan in combination with HCTZ in reducing SBP was recently compared with that seen with HCTZ monotherapies in patients with ambulatory systolic hypertension. 73 Combinations of losartan 50 mg and HCTZ 12.5 mg and losartan 100 mg and HCTZ 25 mg provided greater reductions in clinic and ambulatory BP than HCTZ monotherapies. The enhanced antihypertensive efficacy of losartan-HCTZ combinations with respect to SBP may permit more rapid attainment of BP goals in a greater proportion of patients, thereby circumventing complex and tedious dose-titration schedules.
A recent meta-analysis also clearly showed that the combination of AIIA and HCTZ produces reductions in SBP that are markedly greater than those obtained with AIIA monotherapy. 74 This analysis determined the antihypertensive efficacy of losartan, valsartan, irbesartan, and candesartan in a total of 43 published randomized controlled trials involving 11 281 patients. AIIA plus HCTZ combinations resulted in substantially greater reduction in systolic (16.1-20.6 mmHg) and diastolic (9.9-13.6 mmHg) blood pressure reductions than AIIA alone and responder rates for AIIA/HCTZ combinations ranged from 56 to 70%.
Outcomes studies in systolic hypertension LIFE The LIFE study compared losartan with betablocker atenolol, a conventional antihypertensive drug with documented CV benefits, on cardiac morbidity and mortality in hypertensive patients (aged 55-80 years) with signs of left ventricular hypertrophy (LVH). 75, 76 A predefined subgroup of LIFE involved 1326 patients with LVH aged 55-80 years who also had ISH (SBP between 160 and 200 mmHg and DBP of o90 mmHg). 76 The ISH substudy of LIFE demonstrated that losartan reduced the risk of combined CV morbidity and mortality, especially stroke and CV death, to a greater degree than atenolol for a comparable reduction in blood pressure (28/9 mmHg reduction in both arms). With respect to the primary end point, patients receiving losartan demonstrated fewer events than atenolol (25.1 events vs 35.4 events per 1000 patient years, respectively, RR ¼ 0.75 after adjustment for risk and degree of LVH, P ¼ 0.059, Table 1 ). Compared with atenolol, losartan also decreased the risk of stroke (relative risk (RR) ¼ 0.60, P ¼ 0.02, Figure 3 ), CV mortality (RR ¼ 0.54, P ¼ 0.01), and new-onset diabetes (RR ¼ 0.62, P ¼ 0.04). However, losartan did not significantly affect the risk of MI (adjusted RR ¼ 1.12, P ¼ 0.41). Importantly, compared with atenolol treatment, losartan was associated with significantly lower discontinuation rate as a result of all serious adverse events (Po0.002) and drug-related adverse events (Po0.001).
The results of this substudy of LIFE demonstrate for the first time in patients with ISH that one antihypertensive treatment modality confers CV protective benefits over another proven antihypertensive therapy without clinically meaningful differences in blood pressure reduction. The greater CV benefits of losartan compared with atenolol most likely result from increased protection against the deleterious effects of AII but could also possibly be linked to unique molecule-specific effects of losartan (eg, attenuation of serum uric acid levels 77 or other undefined mechanisms). The decrease in occurrence of new onset diabetes with losartan 78 may be related to an interaction with the peroxisome proliferators-activated receptor-g (PPARg). Irbesartan, telmisartan, and, to a lesser degree, losartan have all been shown to induce PPARg activity, a central regulator of insulin and glucose metabolism. 79 VALUE Results from the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study recently demonstrated BP control values better than those reported in most published large-scale trials. 80, 81 VALUE was designed to compare cardiovascular outcomes in 15 245 eligible hypertensive high-risk patients receiving valsartan or amlodipinebased treatment. The study showed that from 6 months to the end of the trial, both study groups produced decreases in BP (valsartan 3.3/2.6 mmHg and amlodipine 3.0/2.5 mmHg). Target SBP (o140 mmHg) was achieved in 58% of patients in the valsartan group and 64% of patients in the amlodipine group. No significant difference was observed between study groups for the primary composite end point of cardiac morbidity and mortality and for all-cause mortality. However, unequal control of BP in the valsartan and amlodipine groups makes it difficult to draw conclusions 82 comprises a number of trials to compare telmisartan with valsartan, losartan, amlodipine, and ramipril with respect to end-organ protective effects in patients at high risk of renal, cardiac, and vascular damage. The program includes studies on the effects of telmisartan in patients with ISH and is also expected to provide useful information on the value of AIIAs in hypertensive patient populations at high risk of clinical events.
Tolerability and compliance
A key aspect of effectively treating hypertension is the need for tolerability combined with blood pressure lowering-efficacy. This is especially true with respect to patients with systolic hypertension since these patients often require more than one antihypertensive agent to attain target blood pressures and also tend to be elderly and are, thus, more prone to adverse drug reactions. A high degree of tolerability of a combination regimen is particularly important with respect to attaining SBP goals.
A principal reason that many hypertensive patients, including those with ISH, do not attain treatment goals can be attributed, in part, to the high discontinuation rate of antihypertensive medications due to occurrence of side effects. Diuretics (high doses) can give rise to metabolic problems such as hypokalemia, calcium channel blockers frequently produce ankle oedema (short acting calcium channel blockers also increase risk of CV events), ACE inhibitors often induce a persistent dry cough and, in rare instances, angioedema, and beta blockers are associated with a number of chronic adverse events including lethargy, fatigue, muscle weakness and cold extremities, and impotence in men. Approximately 70% of hypertensive patients experiencing side effects are noncompliant with their antihypertensive regimen, and patients experiencing a negative impact on their quality of life have 40-60% higher rate of therapy discontinuation compared with patients whose quality of life is unaffected. 83, 84 In elderly hypertensive patients, AIIAs as a class are well-tolerated, even when administered in combination HCTZ. 85 A particularly remarkable feature of the AIIAs is a safety and tolerability profile comparable to that seen with placebo. 86 As shown in the main LIFE study and in the ISH substudy of LIFE, losartan has an excellent tolerability and adverse event profile. 76 These data are consistent with the observations in short-and long-term trials of losartan in hypertensive patients. 72 In several clinical trials, losartan has been shown to be better tolerated than many other types of antihypertensive agents, including calcium channel blockers, ACE inhibitors, and beta blockers, particularly with respect to oedema, cough, and fatigue. [87] [88] [89] [90] In an analysis of 2900 hypertensive patients enrolled in double-blind trials, losartan alone or losartan in combination with HCTZ was well tolerated, with a similar percentage of patients in losartan-treated and placebo-treated patients reporting clinical adverse experiences. 72 Similarly, in patients with ISH, the tolerability of losartan was also found to be similar to placebo and superior to amlodipine or atenolol. 50, 52, 76 The excellent tolerability of losartan alone or in combination with HCTZ, compared with other principal classes of antihypertensive agents, may have important clinical implications in terms of patients staying on therapy even when antihypertensive strategies involving multiple agents are required.
Conclusions
Often overlooked in clinical practice, systolic hypertension represents a major risk factor for development of CV disease and stroke and requires effective treatment, often involving two or more antihypertensive agents administered in combination. Since AII plays a role in the processes of arterial stiffness, vascular remodelling and endothelial dysfunction, which collectively characterize systolic hypertension, AIIAs may be especially useful in the management of patients with systolic hypertension both for control of SBP and for preventing its CV consequences. This assertion is supported by findings of a substudy of LIFE in hypertensive patients with LVH in which losartan was superior to the beta blocker atenolol in reducing the risk of cardiovascular complications of ISH, particularly stroke. Losartan's documented CV outcomes benefits in the ISH cohort of the LIFE study 76 and its excellent tolerability (alone or in combination with HCTZ) compared with other principal classes of antihypertensive agents, as consistently reproduced in different studies and populations, 72, [87] [88] [89] [90] are likely to have important therapeutic ramifications for the management of SBP. A high degree of tolerability is especially important with respect to patients with systolic hypertension since these patients often require more than one antihypertensive agent to attain the target blood pressures.
